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ABSTRACT OF THE DISSERTATION 
 
In Vitro-Reconstituted Virus-like-particle Delivery 
 of Self-Amplifying RNA Genes 
by 
Adam Min Biddlecome 
Doctor of Philosophy in Biochemistry, Molecular, and Structural Biology 
University of California, Los Angeles, 2019 
Professor William M. Gelbart, Chair 
 
The delivery of RNA genes has great potential in a range of therapeutic applications. A 
couple of main limitations for RNA-based therapies include its vulnerability to ribonuclease 
(RNase) digestion, and its transient and low expression levels due to its lack of amplification. 
Accordingly, a gene delivery platform that includes self-amplifying mRNA inside a protective 
capsid allowing for cell targeting and uptake could represent a major step forward in mRNA-
based gene therapy.  
The self-amplifying nature of viral-encoded RNA-dependent RNA polymerases (RdRp) 
of Nodamura virus holds promise in the development of a platform for self-amplifying RNA 
gene delivery.  To protect and assist in uptake of mRNA encoding an RdRp coupled to a gene of 
interest, plant virus-like-particles (VLPs) are a strong candidate.  Cowpea chlorotic mottle virus 
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(CCMV) capsid protein has been shown to be able to package in vitro heterologous mRNAs, and 
also to make the genes available to mammalian cells. To better characterize the uptake and 
amplification in mammalian cells of RdRp-associated genes (also called a replicon, because of 
its self-amplifying nature), both when naked or encapsidated, reporter genes such as enhanced 
yellow fluorescent protein (EYFP) or luciferase were used. 
In collaboration with the German pharmaceutical company Boehringer Ingelheim (B-I), 
evaluation of possible efficacy of this platform for a cancer vaccine was explored by 
incorporation of a model antigen (Ovalbumin epitope, SIINFEKL) sequence into the RNA1 of 
Nodamura virus. From in vitro studies involving incubation of OVA-replicon-VLPs, we 
observed that CCMV VLPs can be taken up by dendritic cells, where replication then occurs to 
promote increased production of antigen. Flow cytometry analysis revealed increased expression 
of maturation markers, and assaying the dendritic cell content by qPCR showed a significant 
number of SIINFEKL epitope-containing RNA. After these OVA-replicon-VLPs are injected 
into mice, a population of SIINFEKL-specific CD8+ (cytotoxic) T cells results.  
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Chapter 1: Introduction 
The delivery of RNA genes has great potential in a range of therapeutic applications. 
Nearly any sequence of mRNA can be generated at a reasonable cost, whether it be encoding 
natural or de novo proteins. Compared to DNA gene delivery, mRNA has the advantage that 
there is no nuclear localization and thus no possibility of genomic integration[Islam 2015]. Some 
disadvantages it poses for gene delivery include its vulnerability to ribonuclease (RNase) 
digestion and its capability to elicit innate immune responses[Schott 2010]. Another limitation 
for in vivo applications is that gene expression in cells does not have any amplification, resulting 
in only transient and low expression levels. 
Accordingly, a novel gene delivery platform that includes self-amplifying mRNA inside 
of a protective capsid could represent a major step forward in mRNA-based gene therapy. We 
address these issues by using viral replicons (self-replicating RNA molecules) for the self-
amplification, and self-assembled virus-like particles (VLPs) for the protection, specifically 
using the RNA-dependent RNA polymerase (RdRp) from Nodamura virus (NoV) and capsid 
protein (CP) from Cowpea Chlorotic Mottle virus (CCMV). The CCMV CP is particularly well-
suited to package a replicon because it has been shown to package in vitro any heterologous 
RNA that is not much longer than the length of the wild type (WT) genome[Cadena-Nava 2012]. 
Nodamura virus has an RdRp of about 3000 nt, suitable for packaging by this plant CP because it 
is close in length to CCMV’s genomic RNA. Although it is an insect virus, Nodamura is known 
to be functional in mammalian cells[Garrett 1992].  
NoV is a positive-sense RNA virus with a bipartite genome that is co-packaged in the 
same virion. Similar to CCMV, the capsid has 180 copies of a single capsid protein and a 
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diameter of around 30 nanometers. NoV is part of the Nodaviridae family viruses, which 
includes the betanodavirus genus with fish as the natural host, and alphanodavirus genus whose 
hosts includes various insects, mammals, and fish. NoV (part of the alphanodavirus genus) was 
the first species of the Nodaviridae family discovered, and owes its name to the Japanese village 
of Nodamura, Iwate Prefecture where it was first isolated from Culex tritaeniorhynchus 
mosquitoes[Tesh 1980]. From infected mosquitoes, NoV can be transmitted to cause disease in 
suckling mice. Furthermore, it causes paralysis and death in suckling mice and hamsters when 
injected, but no disease in adult animals. In insect hosts, NoV causes stunting, paralysis, and 
death[Owens 2012]. 
 Figure 1 depicts the viral life-cycle of NoV. This positive-sense genome consists of two 
RNA molecules, the larger of which includes the RNA1 (3204 nt) gene that encodes for the 
RdRp, and a subgenomic RNA3 (1336 nt) that encodes for the B2 protein that suppresses host 
cell RNA interference[Gant 2014]. The other molecule is the RNA2 that encodes for the capsid 
protein. Studies on NoV and closely related Flock House virus (FHV) have elucidated much 
about the viral lifecycle, including the mechanism by which their RdRps self-amplify their own 
genes. Upon entering the cell, the cytosolic path to replication begins with translation of the 
RdRp (also referred to as protein A). The RdRp then binds to the 3’ end of RNA1 and generates 
a complementary minus strand. This double-stranded intermediate can then undergo replication 
by synthesis of a full positive strand from the minus stand. Another possibility is transcription of 
a positive-sense subgenomic RNA3 which encodes for proteins B1 and B2. While protein B2 is 
known to be an RNA silencing suppressor, even shown in certain mammalian cell lines to 
enhance RNA accumulation[Johnson 2004], protein B1 is of unknown function. RNA2, also a 
positive-sense and directly translatable RNA, has untranslated regions that promote its own 
 
 
3 
 
replication by the RdRp. The full capsid protein alpha assembles around each copy of RNA1 and 
RNA2, where capsid protein alpha undergoes cleavage prior to cell entry to capsid protein beta 
(the mature capsid protein) and gamma (responsible for breaching the host cell 
membrane)[Banerjee 2008]. In addition to replicating in natural hosts such as Drosophila cells, 
NoV has been shown to also have strong RdRp-dependent replication in mammalian 
cells[Garrett 1992]. Further, it has been demonstrated that – not only its own genes - but also any 
gene of interest can be amplified if inserted into the subgenomic region of RNA1 directly after 
the RdRp open reading frame and before the 3’ untranslated region (UTR)[Gitlin 2014]. 
 
Figure 1: Protein synthesis in the lifecycle (see discussion in the text) of  NoV[18]. 
CCMV is a positive-sense RNA plant virus with a multipartite genome encoding four 
genes contained in three single-stranded RNA (ssRNA) molecules. Like NoV, CCMV (whose 
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structure is shown in figure 2) is a spherical, icosahedral virus with a Caspar-Klug triangulation 
number of 3 (T=3 capsid)[Caspar and Klug 1962]. Figure 2 shows the icosahedral symmetry of 
CCMV, as determined by X-ray diffraction to a resolution of 3.2 Angstroms[Speir 1995]. 
demonstrates the capsid protein organization into this icosahedral symmetry. Our lab has 
demonstrated that the CCMV capsid protein can package any of a large variety of heterologous 
ssRNA in vitro, as long as the nt length does not significantly exceed that of the largest of the 
CCMV RNAs (3200nt). These in vitro assembled capsids are called virus-like-particles (VLPs), 
and have been shown to lend protection to the encapsidated RNA when the VLPs are incubated 
with RNases. Further, when CCMV VLPs containing fluorescent protein genes in mRNA or 
replicon form are transfected into mammalian cells, fluorescence is observed in the cells, 
confirming that the packaged cargo is being made available for translation within the 
cytosol[Azizgolshani 2013].  
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Figure 2: Structure of CCMV determined by X-ray Diffraction to a resolution of 3.2 
Angstroms  
To better characterize the uptake and amplification in mammalian cells of RdRp-coupled 
genes – both when naked or encapsidated – reporter genes such as enhanced yellow fluorescent 
protein (EYFP) or luciferase are used. A few modifications are required in order for RNA1 of 
NoV to be successfully transcribed and remain an active replicon while incorporating a gene of 
interest (GOI). Firstly, the plasmid construct for this replicon begins with a T7 promoter. At the 
start of RNA3, which makes up the subgenomic region, there is a premature stop codon 
introduced in the reading frame of the B2 RNA RNAi-silencing gene to provide the dual 
advantages of having expression of only the protein of interest (POI) from subgenomic 
replication while limiting the introduction of exogenous proteins. Since the GOI is both in the 
same reading frame and is initially translated along with the RdRp, a self-cleaving peptide 
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sequence (T2A peptide) derived from Thosea asigna virus is inserted immediately before the 
GOI. This replicon construct is described in more detail in Chapter 2, including a schematic in 
figure 3.  
The first gene coupled to the replicon in this way was EYFP, a replicon provided by Dr. 
Leonid Gitlin of Dr. Raul Andino’s group at UCSF. They also investigated the possibility of 
gene insertions into the subgenomic region of NoV[Gitlin 2014]. From transfections of baby 
hamster kidney (BHK) mammalian cells with this eYFP-replicon, we were able to follow the 
viral lifecycle by observing the emergence of fluorescence after 8 hours and following its gradual 
decrease after about 24 hours. In order to quantify the increased amount of protein expression 
due to amplification of these replicons, a luciferase replicon was also made. After transfection of 
equal copy numbers of either luciferase mRNA or luciferase-replicon mRNA, the luciferase 
activity was quantified using a luminometer at timepoints from 8 hours to 3 days. The luciferase-
replicon generated at least 10 times the number of luciferase molecules as the luciferase mRNA 
over the course of the three days. 
In collaboration with the German pharmaceutical company Boehringer Ingelheim (B-I), 
evaluation of possible efficacy of this platform for a cancer vaccine was begun by incorporation 
of a model antigen (Ovalbumin epitope) sequence into the replicon. Chapter 3 is a reformatted 
version of the published “Delivery of self-amplifying RNA vaccines in in vitro reconstituted 
virus-like particles”[Biddlecome 2019]. Because many immune cells are naturally primed to 
detect foreign virus particles and take them up by endocytosis, the targeting problem is already 
aided by the use of these VLPs.  The sustained amplification of the antigen by the replicon will 
lead to increased translation of the model antigen, and this should allow for greater Ovalbumin 
antigen presentation by the major histocompatibility complex (MHC) of the immune cell. 
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Experiments involving incubation of EYFP-replicon VLPs with mouse or human dendritic cells 
– done in collaboration with the B-I corporate research labs in Ridgefield, Connecticut – have 
shown that VLPs are gaining entry into the dendritic cells. The dendritic cells incubated with 
VLP-packaged EYFP-replicon RNA exhibit greater expression of intracellular RNA and 
maturation markers than do the corresponding “naked” EYFP-replicon mRNA samples. 
Fluorescence activated cell sorting (FACS) allow for quantification of multiple surface antigens 
including our vaccine epitope or other antigens indicative of dendritic cell maturation.  
Since most vaccines are administered incrementally in doses, an important factor is how 
the drug/vaccine is affected by existing immunity against the exposed, outer, portion of our 
VLPs. Antibodies were generated in Ridgefield against CCMV CP by immunizing mice with 
CCMV VLPs containing a non-translated RNA. These CCMV CP antibodies were pre-incubated 
with EYFP-replicon VLPs before incubating the VLPs with immature dendritic cells, leading to 
the observation of greater dendritic cell maturation compared to that of “naïve” VLPs, i.e., ones 
not exposed to antibodies. This work, as well as the mouse vaccination studies carried out by our 
B-I collaborators in Vienna, Austria, is described in Chapter 3.  In particular, in vivo efficacy is 
demonstrated through a several-week serial immunization of mice by intravenous injection with 
the Ovalbumin-replicon VLP, Ovalbumin-replicon mRNA, or Ovalbumin protein, followed by 
assays of cytotoxic T-cell response, specifically the fraction of generated Ovalbumin-sensitive T 
cells.  
Since RNA1 of NoV is already about the size of each genomic RNA packaged into 
CCMV, there is a limitation on the size of GOI that can be inserted. A promising avenue to allow 
for amplification of larger GOIs involves keeping RNA1 of NoV unchanged, and inserting the 
GOI into the also-replicated RNA2 of NoV which is also replicated. A previous study has shown 
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that by preserving the untranslated regions of RNA2 it is still replicated, even while substituting 
the capsid protein open reading frame with GFP. Co-transfection of wild-type RNA1 with RNA2 
modified to include luciferase, showed that there is greater replication than both luciferase 
mRNA or the modified RNA2 alone.  This work is described in Chapter 4.  
 While having a protected mRNA that can be self-amplified once it enters the cell is a 
promising therapeutic platform, the lack of specificity of delivery may be of concern for certain 
applications. For a vaccine aimed toward stimulation of cytotoxic cells by dendritic-cell MHC 
presentation of an antigen of interest, specific targeting may not be as crucial because dendritic 
cells are already primed to endocytose foreign particles. However, for many other applications 
that could benefit from a replicon-VLP strategy, such as delivery of a necessary protein that is 
compromised in diseased tissue, specific targeting of a cell type could be needed. Conjugation of 
an antibody to target the VLP to certain cell receptors can be used for this targeting. The most 
commonly used amino acids for this conjugation chemistry are lysine and cysteine. While 
CCMV has several surface-exposed lysines in each capsid protein, it was deemed useful to 
generate a cysteine-mutant CCMV so capsid protein subunits would have a single, unique thiol 
group available for maleimide or other chemistry.  This work is described in Chapter 5. 
 Chapter 6 contains a short discussion of future directions, as well as a summary of 
conclusions. 
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Chapter 2: Nodamura replicon-containing molecule 
reporter gene expression and dilution effects 
2.1 Nodamura RdRp-containing self-amplifying construct 
To better characterize the uptake and amplification in mammalian cells of RdRp-
associated genes – both when naked or encapsidated – reporter genes such as enhanced yellow 
fluorescent protein (EYFP) or luciferase are used. In order for RNA1 of NoV to be successfully 
transcribed  and remain an active replicon (an RNA molecule that replicates itself) while 
incorporating a gene of interest (GOI), a few modifications are required. Firstly, the plasmid 
construct for this replicon (depicted in Figure 3, below) begins with a T7 promoter. In the 
beginning of RNA3, which makes up the subgenomic region, there is a premature stop codon 
introduced in the reading frame of the B2 RNA RNAi-silencing gene to provide the dual 
advantages of having expression only of the protein of interest (POI) from subgenomic 
replication while limiting the introduction of exogenous proteins. Since the GOI is both in the 
same reading frame and is initially translated along with the RdRp, a self-cleaving peptide 
sequence (T2A peptide) derived from Thosea asigna virus is inserted immediately before the 
GOI. The first gene coupled to the replicon in this way was EYFP. From transfections of baby 
hamster kidney (BHK) mammalian cells with this EYFP-replicon, we were able to follow the 
viral lifecycle by observing the emergence of fluorescence after 8 hours and following its gradual 
decrease after about 24 hours.  
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Figure 3: Schematic of the replicon construct used to amplify and express an arbitrary 
gene of interest (GOI). T7 is the transcriptional promoter, and the left and right UTRs are the 5’ 
and 3’ untranslated regions, respectively, of NoV RNA1 that are needed for replication. “RdRp” 
is the NoV RNA-dependent RNA polymerase. T2A is Thosea asigna virus 2A self-cleaving 
peptide that allows the RdRp-GOI polyprotein to function as two independent proteins, 
subsequent to translation. HDV is the Hepatitis Delta Virus ribozyme for ensuring clean RNA 
transcripts.     
         
2.2 Quantitative and qualitative reporter gene studies of replicon expression  
In order to quantify the increased amount of protein expression due to amplification of 
these replicons, a luciferase replicon was also made. After transfection by electroporation of 
equal copy numbers of either luciferase mRNA or luciferase-replicon mRNA into BHK cells, the 
luciferase activity was quantified using a luminometer at timepoints from 8 hours to 3 days, as 
shown in figure 4. The luciferase replicon generated at least 10 times the number of luciferase 
molecules as the luciferase mRNA over the course of the three days. 
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Figure 4: Time course of luciferase expression in BHK 21 cells. Electroporation of 10 million 
BHK cells with an equivalent copy number of replicon (5 µg), or luciferase mRNA (1.25 µg, less 
mass due to its shorter length). The plot shows the number of luciferase molecules as determined 
using the standard curves from the Promega renilla luciferase activity kit. 
While the luciferase activity provides quantitative information about the increased protein 
expression from the replicon, it does not reveal qualitative information like the effect the 
replicon expression could have on cell morphology. To this aim we duplicated the transfection 
conditions, this time with eYFP in the replicon instead of renilla luciferase, and (as shown in 
figure 5), imaged the cells by fluorescence microscopy. After 17 hours there were many brightly 
fluorescent cells, and an approximately 75% transfection efficiency (the percentage of cells 
exhibiting fluorescence when comparing the brightfield image to the fluorescence image). When 
looking at this same plate of BHK cells after 41 hours, some interesting trends present 
themselves. For one, the percentage of cells exhibiting visible fluorescence decreases. Also, 
many of the fluorescent cells are round, indicative of dead or weak cells that are loosely attached. 
A fair number of detached cells were observed as early as 17 hours, some of which results from 
the harsh transfection method of electroporation. Still, the observations at 41 hours showing the 
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majority of fluorescent cells being detached from the plate suggests that an overabundance of 
replication can be damaging to the cell.  
               
                
Figure 5: Fluorescence and brightfield microscope images of cells transfected with eYFP-
Replicon after 17 and 41 hours. 
 
2.3 Dilution experiments of replicon for effects on expression 
While these studies utilize reporter genes in order to study the replicon, ultimately the 
aim is to use this replicon-VLP system as a therapeutic. One of the most expensive components 
of this platform is synthesizing capped RNA. The plasmid containing the replicon is transcribed 
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by a T7 promoter, and it is known that for each G nucleotide (up to 3 G’s) at the end of this 
promoter sequence, the greater the yield of RNA from transcription. Since transcription using a 
T7 RNA polymerase begins with the first G nucleotide, the current replicon includes a single G 
at the beginning of the transcript. The RNA1 of nodamura naturally includes a G as its first 
nucleotide, so we wanted to investigate if adding the two extra Gs could increase transcriptional 
yield, and also to see if it has an effect on replication. As expected, the addition of the two extra 
Gs did increase the yield from transcription. When luciferase-replicon mRNAs with one and with 
three Gs are transfected in parallel into BHK cells, a 40% decrease in luciferase activity for the 
extra-Gs sample suggests that replication is being partially compromised. This attenuation from 
the extra Gs might be helpful to reduce the strain on cells that are becoming sick from host 
resources being diverted to support generation of exogenous proteins.  
 Another method explored for attenuating the replicon activity, was to deliver less to each 
cell. While a transfection experiment involves a great excess delivered to each cell, for in vivo 
applications a much smaller number of molecules make it into each cell. We performed 
transfections at varying numbers of luciferase mRNA and replicon in order to understand the 
dose dependence for each. Lipofectamine forms cationic liposomes around RNA.  The cationic 
liposomes work to permeabilize cell membranes to allow entry of nucleic acid. It is important in 
these experiments to maintain the same number of lipoplexes so each cell encounters at least one 
lipoplex even at low copy number of transfected mRNA; accordingly, the total mass of RNA for 
each transfection is maintained by addition of uncapped – and therefore untranslatable – RNA of 
similar length (pTRI-XEF for luciferase mRNA, and pB1/B3 for luciferase replicon).  
 While for luciferase mRNA we observed a roughly linear dependence of activity with 
increasing mass of mRNA transfected, the dose dependence for the replicon is markedly 
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different. A time course for high concentrations of separately transfected luciferase mRNA and 
replicon reveal similar profiles of luciferase activity – see figure 6. The maximum number of 
luciferase molecules reach similar peaks, and the decline over time is only moderately extended 
for the luciferase replicon samples, but at later time points the replicon cell samples show more 
signs of sickness/death than the samples treated with luciferase mRNA.  
 At low concentrations of mRNA, the luciferase activity for the mRNA samples is very 
low.  In contrast, the activity for the replicon is only slightly decreased compared to the 
transfection that involves 40 times the mass of replicon mRNA – see Figure 7. In fact, we find 
that luciferase activity plateaus at higher concentrations of transfected replicon. We see similar 
or even greater numbers of luciferase molecule as the number of replicon molecules transfected 
is decreased. Additionally, we see an extended period of time during which there is significant 
replication for lower concentrations of replicon.   
 
Figure 6: Time course of luciferase expression in BHK 21 cells with higher concentration 
transfection. Cells were transfected using lipofectamine with either 500 ng of replicon or 125 ng 
of luciferase mRNA.  
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Figure 7: Time course of luciferase expression in BHK 21 cells with lower concentration 
transfection. Cells were transfected using lipofectamine with either 12.5 ng of replicon or 3 ng 
of luciferase mRNA.  
 These dilution experiments showed that low numbers of replicon can still result in 
significant levels of protein expression of any gene of interest. At low numbers of replicon 
making into a cell, as would be the probable scenario for an in vivo application, we could have an 
amplification of protein yield without the detrimental effects of too much replication, as seen in 
figure 5.  
 
2.4 Materials and Methods 
Cloning of Replicon Constructs 
Refer to section 3.5, Cloning of Replicon Constructs 
In Vitro transcription of replicon, reporter mRNA, and carrier RNA 
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The plasmids were linearized with XbaI and subsequently purified using QIAquick PCR 
purification columns from Qiagen (Valencia, CA, USA). The linearized DNA was transcribed 
with T7 RNA polymerase. The buffer composition of the reaction was 40 mM Tris pH 7.5, 25 
mM MgCl2, 4 mM µl DTT, and 2 mM spermidine. The rNTP concentration was 7.5 mM. 
Incubation was for 3 hours at 37°C, followed by a 30-minute incubation with turbo DNase at the 
same temperature. The resulting RNA was purified using the RNeasy mini kit from Qiagen, and 
replicon and reporter gene RNA was then capped using the Vaccinia Capping System from New 
England Biolabs (Beverly, MA, USA).  This process added a 7-methylguanylate cap structure to 
the 5’ end of RNA in the presence of the capping enzyme, reaction buffer, GTP, and the methyl 
donor, SAM. The in vitro transcription and capping were both done in the presence of RNase 
inhibitors to preserve the RNA, and the capping mixture was again purified by an RNeasy mini 
column (Qiagen). 
Electroporation of BHK 21 cells 
In preparation for electroporation, cells were passaged the day before until they were at about 70-
90 percent confluence. The cells were washed with chilled and RNase-free PBS, after aspirating 
the media. Trypsin-EDTA (0.25%) was added to detach cells, then after cell detachment, media 
was added back to standard capacity (10 ml for 10-cm, and 25 ml for 25-cm plates). The cell 
mixture was dispensed into tubes, and centrifuged at 500xg for 3 minutes at room temperature. 
After aspiration, pellets were washed in more PBS and trypsin added up to half initial the 
amount. This washing step was repeated, again halving the amount of trypsin.  
Cells were counted using a hemocytometer. 10 µl of the 50-ml cell suspension was pipetted 
between the hemocytometer and the cover slide. Using a cell counter, the number of cells in each 
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larger grid was taken(4-5 bigger square grids for greater accuracy).  The relation for determining 
total cells in suspension was the following: 
# 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
# 𝑏𝑖𝑔𝑔𝑒𝑟 𝑠𝑞𝑢𝑎𝑟𝑒
× 104 
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
× 50 𝑚𝑙 = # 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 
 
Electroporation with the known number of washed, healthy cells involved spinning the cells 
down and resuspending them in a volume that gave a concentration of 20 million cells/ml. 500 µl 
of cells were mixed with 5 µg mRNA and then dispensed into a cuvette. The gene pulse was set 
to high range, high capacitance to 25, voltage to 15 volts. After pulsing twice, cells were replated 
onto a 10-cm cell culture plate. The cuvette was washed with 500 µl buffer to recover the 
remaining cells.  
Lipofectamine Transfection, including RNA dilutions, of BHK 21 cells 
Refer to section 3.5, BHK Cell Culturing and Transfections 
Luciferase Assay 
Refer to section 3.5, Luciferase Assay 
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Chapter 3: Self-amplifying RNA vaccines in in vitro 
reconstituted virus-like particles 
 
Abstract 
Many mRNA-based vaccines have been investigated for their specific potential to 
activate dendritic cells (DCs), the highly-specialized antigen-presenting cells of the immune 
system that play a key role in inducing effective CD4+ and CD8+ T-cell responses. In this chapter 
we report a new vaccine/gene delivery platform that demonstrates the benefits of using a self-
amplifying (“replicon”) mRNA that is protected in a viral-protein capsid. Purified capsid protein 
from the plant virus Cowpea Chlorotic Mottle Virus (CCMV) is used to in vitro assemble 
monodisperse virus-like particles (VLPs) containing reporter proteins (e.g, Luciferase or eYFP) 
or the tandem-repeat model antigen SIINFEKL in RNA gene form, coupled to the RNA-
dependent RNA polymerase from the Nodamura insect virus. Incubation of immature DCs with 
these VLPs results in increased activation of maturation markers – CD80, CD86 and MHC-II – 
and enhanced RNA replication levels, relative to incubation with unpackaged replicon mRNA.  
Higher RNA uptake/replication and enhanced DC activation were detected in a dose-dependent 
manner when the CCMV-VLPs were pre-incubated with anti-CCMV antibodies. In all 
experiments the expression of maturation markers correlates with the RNA levels of the DCs. 
Overall, these studies demonstrate that: VLP protection enhances mRNA uptake by DCs; 
coupling replicons to the gene of interest increases RNA and protein levels in the cell; and the 
presence of anti-VLP antibodies enhances mRNA levels and activation of DCs in vitro. Finally, 
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preliminary in vivo experiments involving mouse vaccinations with SIINFEKL-replicon VLPs 
indicate a small but significant increase in antigen-specific T cells that are doubly positive for 
IFN and TFN induction.                                
 
Keywords: self-replicating RNA, in vitro self-assembly, virus-like particles, dendritic cell 
activation, successive-vaccination boosts 
 
3.1 Introduction to a replicon-based mRNA VLP delivery platform as a 
vaccine 
The delivery of RNA genes has great potential in a range of therapeutic applications[Lam 
017, Geall 2012, Brito 2014, Chahal 2016, Rohovie 2017], with the advantage – compared to 
DNA gene delivery – that there is no nuclear localization and thus no possibility of genomic 
integration. Some disadvantages it poses for gene delivery include its vulnerability to 
ribonuclease (RNase) digestion and – in the case of non-vaccine genes – its triggering of innate 
immune responses[Shoggins 2011, Schott 2010]. Another limitation for in vivo applications is 
that gene expression in targeted cells does not have any amplification, resulting in transient and 
low expression levels. Accordingly, a gene delivery platform that includes self-amplifying 
mRNA inside a protective capsid allowing for cell targeting and uptake[Destito 2007, Hovlid 
2012, Kovacs 2007, Stephanopoulos 2010] could represent a major step forward in mRNA-based 
gene therapy. We address these issues by using viral replicons (self-replicating RNA molecules) 
for the self-amplification, and in vitro self-assembled virus-like particles (VLPs) for the 
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protection, specifically using the RNA-dependent RNA polymerase (RdRp) from Nodamura 
virus (NoV) and capsid protein from Cowpea Chlorotic Mottle virus (CCMV).  
NoV is a positive-sense RNA insect virus with a bipartite genome whose two molecules 
are co-packaged in the same virion[Johnson 2003]. The larger RNA molecule includes the RNA1 
[ 3200 nucleotides (nt)] gene that encodes for the RdRp, and a subgenomic RNA3 (  400 nt) 
encoding the B2 protein that suppresses host-cell RNA interference[Sullivan 2005]. The other 
molecule is the (  1350 nt) RNA2 that encodes the capsid protein. In addition to replicating in 
natural insect hosts such as Drosophila, NoV has been shown to also have strong RdRp-
dependent replication in mammalian cells[Johnson 2004]. Further, it has been demonstrated that 
– not only its own genes - but also any gene of interest can be amplified if inserted into the 
subgenomic region of RNA1 directly after the RdRp open reading frame and before the 3’ 
untranslated region (UTR)[Gitlin 2014].   
CCMV is a positive-sense RNA plant virus with a tripartite genome of four genes 
contained in three single-stranded RNA (ssRNA) molecules[Speir 1995]. Like NoV, CCMV is a 
spherical, icosahedral virus whose capsid has a Caspar-Klug triangulation number of 3[Caspar 
1962]: each of the CCMV ssRNAs is separately packaged in a T=3 shell of 180 subunits, 
organized as 12 pentamers and 20 hexamers of a single capsid protein[Speir 1995].  It has been 
demonstrated that the CCMV capsid protein can package any of a large variety of heterologous 
ssRNA in vitro into wildtype capsids, as long as the length lies in the range 2500-4200nt so that 
it does not significantly differ from that (3200nt) of the largest of the CCMV RNAs[Cadena-
Nava 2012, Garmann 2014a, Garmann 2014b, Garmann 2016].    These in vitro assembled 
capsids, known as virus-like particles (VLPs) – and in particular ones containing RNA replicons 
– have been shown[Azizgolshani 2013] to both lend protection to the encapsulated RNA when 
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incubated with RNases, and make available its genetic cargo to translation upon delivery to 
mammalian cells. Because of the unique ability of CCMV capsid protein to package 
heterologous RNA into perfectly-monodisperse icosahedrally-symmetric (26-nm/180-protein) 
nanoparticles[Cadena-Nava 2012, Garmann 2014a, Garmann 2014b, Garmann 2016], the virus-
like particles we use as self-replicating gene-delivery vectors are uniquely well-characterized.  
Similar results have been demonstrated with cylindrical VLPs reconstituted with capsid protein 
from Tobacco Mosaic Virus (TMV) and RNA replicons from Semliki Forest Virus, with the 
replicons requiring that a TMV “origin-of-assembly”/packaging sequence be inserted into 
them[Kemnade 2014]. 
It is a feature of our replicon gene delivery platform that the gene of interest is coupled to 
the replication and translation of the NoV viral components, so that it has the capability of being 
used for a large array of possible therapies. Here we use the reporter proteins luciferase and 
enhanced yellow fluorescent protein (eYFP) to characterize and quantify the coupling of RNA 
replication and protein expression by the replicon. We then evaluate the efficacy of this platform 
for delivering antigens in RNA form by incorporating into the replicon a model antigen sequence 
(Ovalbumin epitope SIINFEKL[Carbone 1992]). Since many immune cells are naturally primed 
to detect foreign virus particles and take them up by endocytosis, the targeting problem is already 
partially solved for these VLPs.  The sustained amplification of the antigen sequence by the 
replicon leads to increased translation of the model antigen, and this allows for greater marker 
activation and Ovalbumin antigen presentation by the major histocompatibility complex I (MHC 
I) of the immune cell – see Figure 8.  
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Figure 8. Schematic of DC activation triggered by VLP delivery of a self-replicating 
vaccine. Upon uptake (1), disassembly (2) of the VLP makes its RNA gene content accessible to 
the ribosomal machinery (red small and large subunits). Of the two protein gene products – the 
RdRp of the Nodamura virus, and the tandem OVA SIINFEKL epitope repeats – only the RdRp 
(green blob) is shown (3). There follow (4) many rounds of replicon amplification (by the RdRp) 
and translation of OVA repeats (long red squiggles), and subsequent processing (5) of the repeats 
by proteasomes (grey cylinders) and charging (6) of MHC-I molecules (blue Ys) with individual 
SIINFEKL epitopes (short red squiggles), which are then secreted (7) for presentation at the 
plasma membrane, along with CD 80, 86, and MHC-II molecules (lollipops).    
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In this paper we demonstrate that amplification of reporter genes by the NoV replicase 
results in much greater protein expression than an equal copy number of the reporter gene 
mRNA alone. Further, when immature DCs are incubated with VLPs containing this replicon 
mRNA significant increases in DC maturation and RNA levels of the gene of interest (eYFP or 
the tandem OVA SIINFEKL epitope) are observed. The samples with unpackaged mRNA or 
replicon mRNA show no perceptible change in maturation or RNA levels compared to negative 
controls, pointing up the fact that the VLP effectively protects the mRNA and helps it gain entry 
into the DCs.  
Because many vaccines need to be administered incrementally in doses, an additional 
important factor is how the drug/vaccine is affected by existing immunity against the exposed 
outer portion of VLPs. Accordingly, antibodies were generated against CCMV capsid protein 
(CP) by immunizing mice with CCMV VLPs containing a non-translatable RNA. VLPs 
containing eYFP-replicon or OVA-replicon were incubated with these polyclonal anti-CCMV 
CP antibodies before being added to immature DCs, leading to enhanced DC maturation and 
RNA levels of eYFP or OVA compared to those of “naïve” VLPs, i.e., ones that have not been 
exposed to antibodies.  
Finally, in preliminary in vivo experiments, we have measured the T-cell response to a 
series of mouse vaccinations with VLPs containing the SIINFEKL antigen in replicon form, and 
find a small but significant population of SIINFEKL-sensitive T cells that are doubly-positive in 
INF and TFN cytokine production.   
 
 
 
 
24 
 
Hijacking of the Nodamura virus life cycle 
Figure 9A, which is adapted from Ball, et al.[25] shows the protein synthesis components 
of the NoV life cycle, depicting schematically the replication and translation strategies of this 
two-molecule/four-gene positive-sense RNA virus. Molecule RNA1 is translated directly to yield 
“Protein A”, the RdRp that binds RNA1 and RNA2 and replicates them strongly through 
successive rounds of -strand and +strand synthesis. As part of the replication of RNA1 its -
strands are “transcribed” to give not only +strands of the full-length RNA1, but also mRNA 
(subgenomic [sg] RNA3) that is translated to either a B1 protein in the same reading frame as the 
RdRp, or a B2 protein in an alternate reading frame. The B2 protein is known to suppress host-
cell RNA interference[Johnson 2004], whereas the function of B1 has not yet been determined. 
RNA2 is translated to capsid protein alpha, which assembles into a capsid in which the protein 
matures by undergoing autocatalytic cleavage to yield capsid protein beta and the membrane-
permeabilizing peptide gamma. 
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Figure 9. A Protein synthesis in the lifecycle (see discussion in the text) of  NoV[18].                     
B Schematic of the replicon construct used to amplify and express an arbitrary gene of 
interest (GOI). T7 is the transcriptional promoter, and the left and right UTRs are the 5’ and 3’ 
untranslated regions, respectively, of NoV RNA1 that are needed for replication. “RdRp” is the 
NoV RNA-dependent RNA polymerase. T2A is Thosea asigna virus 2A self-cleaving peptide 
that allows the RdRp-GOI polyprotein to function as two independent proteins, subsequent to 
translation. HDV is the Hepatitis Delta Virus ribozyme for ensuring clean RNA transcripts.            
C Table of genes of interest, inserted one at a time into the replicon depicted in B. 
 
3.2 Generation and characterization of ovalbumin epitope-containing replicon 
VLPs 
In the present work we dispense with RNA2 and add a gene of interest (GOI) to the 
subgenomic sequence of RNA (see METHODS), as shown in Figure 9B. Any gene of interest 
can be coupled to the replication of the RdRp by inserting it in this way, but its length must be 
less than about 1000 nt in order to guarantee in vitro packaging[Cadena-Nava 2012, Garmann 
2014a, Garmann 2014b, Garmann 2016] of the ensuing replicon by CCMV CP into a single 
RNase-resistant wildtype (T=3) capsid. This GOI-containing replicon is constructed in a plasmid 
that can be transcribed in vitro, and includes other important features such as a self-cleaving 
peptide sequence (T2A peptide) derived from Thosea asigna virus, which separates the viral and 
exogenous proteins to render them functional, and a Hepatitis-Delta-Virus (HDV) ribozyme for 
providing monodisperse RNA transcripts.   
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Depending on the goal of our assay, we use one of several GOIs (see table in Figure 9C): 
eYFP for direct qualitative visualization of replicon replication and translation; Renilla 
Luciferase for quantification of the resulting level of protein expression from the replicon; and 
tandem repeats of the SIINFEKL epitope of Ovalbumin for quantification of DC maturation 
(marker protein expression) and antigen presentation, and for future follow-up in vivo 
experiments assaying T-cell response in mice.                                           
      
Reporter genes in replicon form are strongly replicated and expressed 
Figure 10A shows the time courses for luciferase protein yield from baby hamster kidney 
(BHK) cells transfected by lipofectamine with replicon versus naked mRNA forms of luciferase, 
emphasizing the 30-fold greater yield found for the replicon, and its persistence over several 
days. Along with the 30-fold greater yield of luciferase molecules, a 150-fold increase in RNA 
molecules including the luciferase gene is observed with the replicon (figure 10B).  
A  
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B 
 
Figure 10. A Time course of luciferase expression in BHK-21 cells. Cells were transfected 
with equal numbers of renilla luciferase gene, in mRNA form (“luciferase [luc] mRNA”) – 
including a poly-A tail – or as NoV replicon with luciferase in the sub-genomic region 
(“luciferase replicon [luc-rep] RNA”). The plot shows the estimated number of luciferase 
molecules as determined using the standard curves from the Promega renilla luciferase activity 
kit.   B Number of luc mRNA (solid circles) and luc-rep RNA (solid squares) molecules at 
each of the time points in A. These numbers were determined by real-time quantitative PCR 
(qPCR),  with results for both luciferase activity and qPCR from biological duplicates. Each of 
those biological duplicates was measured in duplicate or triplicate for luciferase activity and 
qPCR, respectively. Of these replicates, the average is plotted with standard deviation (in some 
cases the error bar is narrower than the data point itself, thus is not included). The figure on the 
right is a re-plotting – with an expanded scale in the units of 108 instead of 1010 – of the mRNA 
numbers that are indistinguishable from zero in the figure on the left. 
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Nodamura replicons can be in vitro packaged into and protected by virus-like particles  
Figures 11A and 11B show gel and electron micrograph images and size histograms, 
respectively, of in vitro reconstituted VLPs prepared (see METHODS) from purified CCMV CP 
and in vitro transcribed eYFP replicon RNA. All figures are for samples that have been treated 
with RNase, confirming that the VLPs are able to protect RNA cargo. Note that the reconstituted 
VLPs run a little slower than the wildtype virions because they are prepared from a small excess 
of protein (see discussion in Materials and Methods) that binds to the outside of the self-
assembled capsid.     
Figure 11. Verification of replicon VLP assemblies. A) A native 1% agarose gel with (left to 
right) a NEB 1 kb DNA ladder, wild-type CCMV virion, and reconstituted VLPs containing 
NoV replicon RNA.B) LEFT. Negative-stain electron microscopy (EM) image of in vitro self-
assembled VLPs containing eYFP replicon mRNA. B) RIGHT. Histogram of size distribution of 
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VLPs shown in the electron micrograph, juxtaposed on the corresponding histogram of sizes for 
wildtype CCMV virions. 
 
3.3 RNA quantitation and maturation markers showing activation of 
immature dendritic cells when incubated with replicon-VLPs  
DCs maturation and RNA replication are strongest for packaged replicons 
Figure 12Ai shows panels of CD86, MHCII and CD80 marker activation, determined by 
flow cytometry, following incubation of immature DCs with medium, naked eYFP mRNA, 
CCMV VLPs carrying eYFP mRNA, naked eYFP replicon mRNA, and CCMV VLPs carrying 
eYFP replicon mRNA. Fig. 5Aii shows the RNA levels corresponding to each of these five 
incubations, determined by qPCR, and plotted as numbers relative to those of the housekeeping 
gene beta-actin. Consistent with the well-known fact that DC maturation is extremely sensitive to 
culturing conditions, e.g., to medium and pipetting, marker activation by media is comparable to 
that by our “active” reagents, except for the case of replicon-containing VLPs. RNA replication – 
see Fig. 5Aii – is present only for the replicon reagents and is 100 times greater for the packaged 
replicon. The sensitivity of DC maturation to donor cells is seen in Figure 12B, where DCs from 
a different donor than in 5A are used for incubations with medium (negative control), naked 
eYFP replicon mRNA, and CCMV VLPs carrying eYFP replicon mRNA. Here, while there is 
again comparable maturation associated with medium as with the naked replicon, the activation 
is one to two orders-of-magnitude greater for the VLP-packaged replicon. 
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Figure 12. Expression intensity of activation markers on DCs. A i) Results from a donor 
treated with different conditions of EYFP mRNA or CCMV VLPs. The median fluorescence 
intensity (MFI) of CD86 (left), MHC II (middle) and CD80 (right) was determined by FACS 
assays for cells treated with media only (black bars), eYFP mRNA (blue bars), CCMV VLPs 
carrying eYFP mRNA (red bars), eYFP replicon mRNA (light grey bars), or CCMV VLPs 
carrying eYFP replicon (dark grey bars).  A ii) RNA quantitative PCR (qPCR). The same-donor 
DCs treated/incubated with each of the five reagents in Ai were lysed after 24 hours and eYFP-
specific mRNA levels were determined by qPCR. Their numbers relative to beta-actin multiplied 
by 1000 are plotted. From the same sample of dendritic cells assayed for maturation markers, 
triplicate measurements yielded the plotted average and standard deviation (p value was 
determined using a one-way Anova test). B Maturation markers probed as in Ai but with DCs 
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from a different donor, for incubations with media only (black bars), eYFP replicon mRNA 
(light grey bars), and CCMV VLPs carrying eYFP replicon mRNA (dark grey bars).  
 
Pre-incubation of VLPs with VLP-antibodies enhances DC activation and RNA replication 
To check whether antibodies against the CCMV VLPs can modulate the RNA uptake and 
activation of DCs, mice were immunized three times subcutaneously (see METHODS) with 
CCMV VLPs containing a non-translated RNA. Pre- and post-immune sera were collected and 
antibody titers were determined by ELISA against the CCMV VLPs. As shown in Figure S1, 
strong antibody responses were observed in all of the animals. 
Figure 13 shows (top) the enhancement of DC marker activation when DCs are incubated 
with VLPs that have been exposed to capsid protein antibodies (in the form of serum from 
CCMV-inoculated mice). Here the packaged replicon includes the OVA tandem repeats, rather 
than eYFP. Again the enhanced marker activation associated with the pre-incubated VLPs 
correlates with a much larger enhancement in the level of RNA replication (see Figure 13 
BOTTOM). 
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Figure 13. TOP: Expression intensity of activation markers on DCs treated with pre-
incubated OVA-Replicon VLPs. The median fluorescence intensities (MFIs) of CD86 (left), 
MHC II (middle) and CD80 (right) were determined for cells treated with media only (black 
bars), CCMV VLPs carrying OVA replicon mRNA (grey bars), or CCMV VLPs carrying OVA 
replicon that have been pre-incubated with anti-CCMV VLP (green bars) or naïve serum 
antibodies (blue bars).  
BOTTOM: RNA qPCR. DCs treated with one or another of these three “reagents” were lysed 
and Ova-specific mRNA levels were determined by qPCR (again measured in triplicate as in 
Figure 12 Aii). The p value was determined using a one-way Anova test. 
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Similar results are obtained with the same donor cells for VLPs containing the eYFP 
replicon – see Figure S2 – i.e., marker activation is enhanced by pre-incubation with anti-CCMV 
VLP antibody, again associated with a much greater enhancement of RNA replication. 
 
3.4 Mouse vaccination with ovalbumin-replicon VLPs induces specific T-cell 
response  
In a preliminary in vivo study we vaccinated mice with in vitro reconstituted CCMV 
VLPs containing the SIINFEKL replicon RNA. Three subcutaneous (s.c.) injections consisting 
of 100µg of VLP in a 100µl volume were administered, separated by an interval of one week, 
and on the 4th week ex vivo analyses of spleen T cells were carried out by FACS. The negative 
control experiment (“Ctr”) was a corresponding series of injections of buffer solution, and the 
positive control was the T-cell analysis of a 96:4 mixture of T-cells from wildtype mice and from 
OT-1 mice engineered with a SIINFEKEL-specific T-cell receptor. As seen in Figure 14 there is 
a small (0.4%) but significant T-cell response to the SIINFEKL replicon VLPs. Similarly, there 
is a small but significant increase in the percentage of T cells that are doubly positive for 
induction of both IFN   and TNF; see Figure S3. 
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Figure 14. Percentage of SIINFEKL specific CD8+ T-cells from mice vaccinated three 
times, separated by one-week intervals. Cells isolated from spleens were analyzed ex vivo by 
flow cytometry one week after the last vaccination. 
LEFT: The positive control (“OT-1 pos Ctr”, left-most bar) is the result from a 4:96 mixture of 
splenocytes from an OT-1 mouse (homozygous for the transgenic T cell receptor recognizing 
SIINFEKL in the context of H-2Kb) and from a wildtype mouse; it provides a calibration of 
SIINFEKL-specific T-cell percentages harvested from the vaccinated mice.  “FMO (fluorescence 
minus one) SIINFEKL” refers to a negative control in which the H-2Kb/SIINFEKL Pentamer is 
absent from the fluorochrome mix used for flow analysis. The “Ctr” measurements involve 7 
wildtype mice (1-5, 7&8) vaccinated with buffer solution, while the“SIINFEKL-VLP” data refer 
to mice (9-13, 15-16) vaccinated with buffer with SIINFEKL replicon VLPs.                              
RIGHT: The same data are presented as scatter plots, including the median (line) for each set of 
measurements. An unpaired t-test with Welch’s correction was performed and a significant 
difference between the groups was seen (p=0.0248). 
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3.5 Conclusions  
We have shown that levels of DC activation are significantly enhanced by incorporation 
of reporter genes and model antigens into self-replicating RNA molecules – replicons – that have 
been in vitro packaged into VLPs.  This enhancement of marker protein expression has been 
correlated with a much stronger amplification of RNA replication of the replicons, corresponding 
to RNA levels as much as ten-thousand-fold greater than those of the housekeeping protein beta-
actin. Further enhancement of DC activation and RNA replication – likely facilitated by Fc- 
receptor-mediated[Da Silva 2007] VLP uptake by DCs – has been achieved by pre-incubation of 
the VLPs with antibodies elicited against capsids of the proteins used to package the replicons. 
And this amplification is seen in dendritic cells from different donors and for different reporter 
and vaccine RNA genes. Preliminary in vivo experiments involving vaccination of mice with 
antigen-replicon VLPs show a small but significant generation of antigen-specific T cells that are 
doubly positive in their induction of IFN and TFN cytokines. 
The modest T-cell response reported here provides a proof-of-principle for our RNA 
replicon virus-like particle vaccine platform. In contrast with plasmid-DNA and viral-vector 
delivery systems, in particular those involving lentiviruses, adenovirus, and adeno-associated 
virus, there is no need for genetic information to access the nucleus of the host cell and no 
possibility of integrating genes into the DNA of the host cell. There are also no viral-specific 
immune responses that interfere with efficacy of vaccine boosts. mRNA vaccines have none of 
these drawbacks because they are translated directly in the cytoplasm and gene expression is 
only transient. They also have the advantage that they act simultaneously as adjuvants, because 
they interact with pattern-recognition receptors that elicit innate immune response enhancing the 
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maturation of DCs and induction of adaptive immune response. Further when combined with the 
right RNA replicase gene, the mRNA vaccine is amplified strongly before being translated, 
resulting in a high level of in situ protein expression. Several mRNA replicon vaccines of this 
kind have been reported (see the recent review by Maruggi, et al.[Maruggi 2019], and references 
contained therein), but ours is the first in which the RNA is in vitro reconstituted in a perfectly 
monodisperse, RNase-resistant, spherical protein shell, instead of being “packaged” in less-well-
characterized complexes involving lipids, cationic polymers, or various combinations of these 
components.  In addition, our virus-like particles can be conjugated with ligands that enhance 
their uptake by targeted dendritic cells, and additional RNA genes included to further enhance 
dendritic cell activation and subsequent T cell priming. 
The two essential ingredients of our approach derive from the special properties of two 
different non-mammalian viruses: (1) the insect virus Nodamura provides the self-replicating RNA 
molecule (with its associated RNA-dependent RNA polymerase) into which genes of interest (such 
as the OVA antigen) can be inserted; and (2) the plant virus CCMV provides the capsid protein 
ensuring the in vitro packaging of these replicons and consequent uptake by DCs. Nodamura is 
remarkable insofar as its RdRp functions in mammalian cells and is short enough to be packaged by 
CCMV CP, even after inclusion of interesting reporter genes or model antigens. And CCMV is 
remarkable insofar as its purified CP is uniquely capable of completely packaging, by spontaneous 
self-assembly, essentially any RNA sequence as long as its length does not exceed about 4000nt.  
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3.6 Materials and Methods 
Reagents 
Recombinant human GM-CSF and IL-4 were purchased from R&D Systems (Minneapolis, MN, 
USA). PE-labeled antibodies (Abs) against human CD80, CD86 and MHC II were from BD 
Pharmingen (San Diego, CA, USA) and isotype control Abs from R&D Systems (Minneapolis, 
MN, USA). Complete Freund's Adjuvant, Incomplete Freund's Adjuvant and Lipopolysaccharide 
(LPS; Escherichia coli, O111:B4) were obtained from Sigma (St Louis, MO, USA). The goat 
anti-mouse HRP-conjugated secondary ab (goat anti-mouse IgG-HRP SC-2005, Lot # D1614) 
was purchased from Santa Cruz Biotechnology (San Diego, CA, USA). The BioFXr TMB super-
sensitive one-component HRP microwell substrate was from SurModics (Minneapolis, MN, 
USA) and the BioStack Microplate Stacker from BioTek Instruments (Winooski, VT, USA). 
RPMI-1640 (-L glutamine) and L glutamine were from Thermo Fisher (Waltham, MA, USA) 
and heat-inactivated fetal bovine serum (FBS) from Sigma (F4135-500, 15H095H1).  
 
 
 
 
38 
 
BHK Cell Culturing and Transfections 
BHK-21 cells were cultured in medium composed of high-glucose DMEM medium with 10% 
FBS and penicillin/streptomycin. The incubation conditions were 37˚C and 5% CO2. Standard 
passaging was performed with the involvement of PBS for washing, and 0.25% trypsin-EDTA 
for cell detachment. All the above cell culturing reagents and medium were from ThermoFisher. 
The cells were passaged to 60-90% confluence in 24-well cell-culture-treated plates and, prior to 
transfection, were washed with PBS. For each well, 5 µl of lipofectamine-2000 (Thermo Fisher) 
was diluted with Opti-mem medium (Thermo Fisher) before mixing with 0.5 µg of RNA that is 
also diluted to an equal volume in Opti-mem. Since the replicon is so effective, the masses of 
mRNA prescribed in the lipofectamine-2000 manufacturer’s protocol for the replicon were 
making the cells sick. By diluting the replicon RNA, a similarly large luciferase activity 
compared to higher concentrations of transfected mRNA is observed (especially when compared 
to the equimolar luciferase mRNA). Masses of 12.5 ng of luciferase replicon mRNA and 3 ng of 
luciferase mRNA were diluted with uncapped carrier RNA of similar length up to 0.5 µg, in 
order to achieve a similar number of liposomes per transfection. 
 
Luciferase Assay  
The luciferase assay was performed using the Renilla Luciferase Assay System from Promega 
(Fitchburg, WI, USA), and activity was measured using a Monolight 2010 luminometer. Cells 
were washed with PBS before directly lysing using passive lysis buffer and a cell scraper. 100 µl 
of Renilla luciferase assay reagent was added to a polycarbonate tube and luminescence was 
measured with 10 seconds of integration and a 2-second delay directly after adding 20 µl of cell 
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lysate and mixing. Luciferase activity was performed in biological and assay duplicates for each 
time point.  
 
Cloning of Replicon Constructs                               
The plasmids constructed for these experiments were derived from plasmids kindly provided by 
Dr. Leonid Gitlin, from his work in Prof. Raul Andino’s lab at UCSF. Synthesis was performed 
from Nodamura virus strain Mag115, cDNA using random hexamers and SuperScriptIII 
(Invitrogen). The eYFP-replicon used was the same construct entitled pNoda-B1-FPG in their 
paper. The luciferase-replicon and OVA epitope-replicon plasmids were constructed from their 
construct pNoda-PolT2A-GFP. The luciferase gene for the luciferase-replicon was PCR-
amplified from the plasmid pSP64-Ren Luc-Poly(A) – denoted as SP6 luciferase in Figure 10. 
pSP64-Ren Luc-Poly(A) has the Renilla luciferase open reading frame from pRL null 
(Progema), cloned into the XbaI site of pSP64 Poly(A) vector (Promega). The gene was PCR-
amplified gene using Phusion High-Fidelity Polymerase (NEB), and included NdeI and AgeI 
restriction sites for insertion into the corresponding sites of the pNoda-PolT2A backbone. The 
construction of the OVA epitope-replicon plasmid began with ordering complementary oligos 
encoding the SIINFEKL peptide sequence from IDT. These oligos have flanking NheI and XbaI 
sequences, as well as an overhanging ‘A’ nucleotide at the 3’ ends to allow for ‘TA-cloning’ into 
a pGEM-T Easy Vector (Promega). When the pGEM vector with inserted SIINFEKL sequence 
is digested with a combination of either ScaI/XbaI or ScaI/NheI, the remaining XbaI and NheI 
sites are complementary. This process is repeated to result in a 4X tandem OVA epitope 
sequence, which is then cloned into the pNoda-PolT2A backbone by the same methods as the 
luciferase-replicon. 
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Synthesis of Replicon mRNA-VLPs 
The replicon constructs were linearized with XbaI and subsequently purified using QIAquick 
PCR purification columns from Qiagen (Valencia, CA, USA). The linearized DNA was 
transcribed with T7 RNA polymerase. The buffer composition of the reaction was 40 mM Tris 
pH 7.5, 25 mM MgCl2, 4 mM µl DTT, and 2 mM spermidine. The rNTP concentration was 7.5 
mM. Incubation was for 3 hours at 37°C, followed by a 30-minute incubation with turbo DNase 
at the same temperature. The resulting RNA was purified using the RNeasy mini kit from 
Qiagen, and then capped using the Vaccinia Capping System from New England Biolabs 
(Beverly, MA, USA).  This process added a 7-methylguanylate cap structure to the 5’ end of 
RNA in the presence of the capping enzyme, reaction buffer, GTP, and the methyl donor, SAM. 
The in vitro transcription and capping were both done in the presence of RNase inhibitors to 
preserve the RNA, and the capping mixture was again purified by an RNeasy mini column 
(Qiagen). Generating VLPs first involves isolation of CCMV CP from CCMV. The CCMV was 
purified from infected Cowpea plant leaves. To purify the CP, the virion was loaded into 6 kDa 
dialysis bags, and dialyzed in disassembly buffer (500 mM calcium chloride, 50 mM Tris-HCl 
pH 7.5, 1 mM EDTA, 1 mM DTT, and 0.5 mM PMSF). After dialysis, the disassembled CP-
RNA mixture was pipetted into polycarbonate tubes and centrifuged in a TLA 110 rotor at 95k 
for 2 hours. (This dialysis step and the three described immediately below – for CP purification, 
CP-RNA binding, and capsid formation – were each carried out for 6 hours at 4°C.) Fractions 
were taken after centrifugation, and a threshold A260/280 ratio of 0.6 was used to verify that 
they did not contain RNA. The capsid protein was dialyzed into Buffer B (1 M NaCl, 50 mM 
Tris-HCl pH 7.2, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF). After determining the CP 
concentration with a Nanodrop Spectrophotometer, CP was combined with mRNA at a ratio of 
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12.9 µg of CP to 3µg mRNA (representing the minimum excess of CP necessary for complete 
encapsidation of mRNA) in buffer B but without DTT or PMSF, for a total volume of 100µl. 
This mixture was then dialyzed into RNA Assembly Buffer, RAB (50 mM NaCl, 50 mM Tris-
HCl pH 7.2, 10 mM KCl, 5 mM MgCl2, and 1 mM DTT), after which the pH was dropped to 
form capsids by dialyzing into Virus Suspension Buffer (50 mM Sodium Acetate, 8 mM 
Magnesium Acetate). Finally, the sample was transferred to RAB without DTT in order to have a 
VLP sample at the necessary neutral pH for biological experiments. Once VLPs have been 
verified (methods for which are described in the following two sections), the mg/ml 
concentration of VLPs is measured using the Nanodrop by dividing the 260nm absorbance by 
5.8, the same factor used when determining the concentration of purified virus. Because of the 
small excess of CP used for complete packaging of RNA, the recovery of VLP mass is about 
80% of the total mass of mRNA and CP used in the assembly. 
 
Verification of Assembly 
After assembly, the first step to verify the formation of homogeneous VLPs is agarose gel 
electrophoresis. A native agarose gel was run at 50 V for 1.5 hours, with the running buffer and 
the 1% agarose gel being made of 100 mM Sodium Acetate and 1 mM EDTA; the staining is 
with ethidium bromide.  For reference, wild-type CCMV virion is included in a separate lane – 
the middle, in Fig. 4A. The assembly mix is treated with RNase and loaded directly onto the gel 
(rightmost lane): the reconstituted VLPs run more slowly because of excess protein adsorbed 
onto their capsids; a small (40%) excess of capsid protein has been used to guarantee complete 
packaging of all the RNA, and it binds to the negative exteriors of the self-assembled VLPs 
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through its cationic N-terminus[Cadena-Nava 2012, Garmann 2014a, Garmann 2014b, Garmann 
2016].  VLP formation from in vitro assemblies has also been verified directly in bulk solution 
by sucrose gradient analysis (see our earlier study of VLPs involving the same lengths of 
RNA[Garmann 2014b] – in particular Fig. 3 there), where we compare the relative sedimentation 
profile peak positions for VLPs, wild-type virions, and virions plus excess protein and correlate 
them with the corresponding band positions in the electrophoretic gels.    
 
Electron Microscopy 
The preparation of well-formed intact VLPs was confirmed by negative-stain electron 
microscopy. 6 µl of VLPs is applied to glow-discharged copper grids (400-mesh) coated with 
Parlodion and carbon. After 1 min, the solution is blotted with Whatman filter paper. 6 µl of 1% 
uranyl acetate is then added to the grid. After 1 min, the excess uranyl acetate is removed by 
blotting. The grids are stored overnight in a desiccator and analyzed with a JEM 1200-EX 
transmission electron microscope equipped with a wide-angle (top mount) BioScan 600-W 11K 
pixel digital camera operated at 80 keV. The diameter of the VLPs is estimated by taking the 
geometric mean of two orthogonal measurements of the capsids obtained with ImageJ (U.S. 
National Institutes of Health) software from recorded images. The diameter of 100 VLPs is 
measured in this way and compared to the diameter of wtCCMV that had been previously 
imaged.  
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Generation and culture of monocyte-derived DCs 
To generate immature DCs, CD14- monocytes negatively isolated from human peripheral blood 
mononuclear cells were cultured in a 24-well plate (1.0 × 106 cells/ml/well) with RPMI-1640 (-L 
glutamine) medium containing 1 × L glutamine and 10% heat-inactivated fetal bovine serum for 
5 days. The donors were anonymous, but the number designation of PBMC for the figures 
included in this article are as follows: figure 12 Ai and Aii – A5394, figure 12 B – A5154, figure 
13 – A5167, and figure S2 – A5167. Culture medium was supplemented with recombinant 
human GM-CSF (10 ng/mL) and recombinant human IL-4 (10 ng/mL).   
 
Pulsing of dendritic cells  
On day 5, immature DCs (1.0 × 106 cells/ml/well) were pulsed with naked eYFP mRNA, CCMV 
VLPs carrying eYFP mRNA, naked eYFP replicon mRNA, CCMV VLPs carrying eYFP 
replicon mRNA, CCMV VLPs carrying OVA-replicon mRNA, OVA-replicon-carrying CCMV 
VLPs pre-incubated with anti-CCMV VLP abs or naïve serum abs, and eYFP-replicon-carrying 
CCMV VLPs pre-incubated with anti-CCMV VLP abs or naïve serum abs. DCs stimulated with 
LPS and media were used as a positive and negative control, respectively. Following 24 hours of 
incubation, expression of activation markers for human DCs such as CD80, CD86 and MHC II 
was analyzed using flow cytometry.  
 
Mouse immunization  
C57BL/6Tac mice between 6-8 weeks of age were purchased from Charles River Laboratories 
(Wilmington, MA). They were immunized subcutaneously with CCMV VLPs containing a non-
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translated RNA (20 µg/per mouse/per immunization) on weeks 0, 2, and 4 using Complete 
Freund's Adjuvant for priming and the subsequent boost with Incomplete Freund's Adjuvant. The 
animal use protocol was approved by IACUC committee of Boehringer Ingelheim 
Pharmaceuticals. Serum samples collected one week after the 3rd immunization were evaluated 
by ELISA to determine the antibody titer against CCMV VLPs. Pre-bleed was used as a negative 
control.       
 
Enzyme-linked immunosorbent assay (ELISA) 
To determine the end-point titers, CCMV VLPs were coated onto Immulon 2 HB 96-Well 
Microtiter plates (Catalog # 227, ImmunoChemistry Technologies, Bloomington, MN) at 
0.5µg/mL using PBS overnight at 4 °C. Uncoated surface was blocked using phosphate-buffered 
saline (PBS) containing 3% Bovine Serum Albumin for 1 hr at 37°C. The plates were 
subsequently washed 5× with 0.05% Tween 20 in PBS. Mouse serum serially diluted (three-fold) 
in the blocking buffer was added to each well and incubated for 2 hrs at 37°C. The plates were 
washed 5×, and horseradish peroxidase (HRP)-conjugated secondary ab (goat anti-mouse IgG, 
1:3000 dilution) was added to each well and incubated for 1 hr at 37°C. Plates were washed 5× 
and developed by adding 100 µl BioFXr TMB super-sensitive one-component HRP microwell 
substrate for 5 min. Reactions were stopped with 50 µl of 2 N H2SO4. Plates were read on a 
microplate reader (BioStack Microplate Stacker) at 450 nm. All experiments were performed in 
duplicate.  
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Quantitative PCR  
The Power SYBR® Green Cells-to-CT kit was used for the detection of OVA and eYFP mRNA 
uptake by DCs. Briefly, the passively pulsed dendritic cells were washed twice with ice-cold 1 × 
PBS.  RNALater (200 µl) was added to the well(s).  The plate was sealed with PetriSEAL and 
placed at -80oC. To isolate RNA, the plate was thawed rapidly and an equal volume of ice-cold 1 
× PBS was added to the well(s).  The plate was spun at 1400 rpm for 5 min at 4°C.  The fluids 
were removed carefully and the cell layer was washed again twice with ice-cold 1 × PBS.  The 
cells were lysed for 5 min at room temperature in 50 µl of Lysis solution supplemented with 
DNase I (all supplied in the Power SYBR® Green Cells-to-CT kit). The reactions were then 
stopped with 1/10 volume stop solution and left at room temperature for 2 min.  10 µl of the 
lysate was added to the reverse transcription reaction cocktail that contained 1× SYBR RT buffer 
with 1× RT Enzyme mix. The reaction was run at 37°C for 1 hr followed by a 5-min 95°C heat 
kill of the enzyme. 
Four microliters of the reverse-transcribed material was added to 16 µl of gene-specific forward 
and reverse primers at 400 nM in the PowerSYBR Green PCR master mix.  The samples were 
run using a Viaa7TM cycler (95°C for 10 min to activate the enzyme; 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute to amplify the sequence of interest).  The CT values were 
generated by the Viaa7 program.  Relative expression of the pulsed mRNA was calculated by 
finding the differences between pulsed mRNA CT values and the CT value for the ACTB 
housekeeping gene generated from the same cells by using the relation:  RelExp = POWER (2 -
(CT value)). 
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For quantifying luciferase RNA in BHK cells in the Figure 10 time course, a different qPCR 
approach was utilized. The transfected BHK cells were lysed using buffer RLT in the RNeasy 
mini kit from Qiagen. Before purifying with the standard RNeasy mini kit protocol, the lysate 
was passed through a QIAshredder column (Qiagen) in order to remove insoluble debris. After 
purification, the concentration was verified with a Nanodrop Spectrophotometer, and 1 µg was 
reverse transcribed using M-MuLV reverse transcriptase from NEB. The flanking luciferase 
qPCR primer was used to synthesize the cDNA. In order to quantify RNA number, a standard 
curve with known concentrations of luciferase replicon RNA from 100 pg to to 10 fg was 
assayed by qPCR using the standard protocol for SsoAdvanced Universal SYBR Green 
Supermix (Bio-Rad, Irvine, CA, USA). The concentration of the luciferase amplicon primers 
used was 200 nM. For the time course samples, 100 pg and 10 pg cDNA of the luciferase mRNA 
and replicon transfected cells were assayed by qPCR, respectively. 
 
Mouse vaccinations 
C57BL/6Tac female mice were provided by Taconic Denmark. The mice were transferred to the 
local AAALAC accredited animal facility at Boehringer Ingelheim RCV GmbH & Co KG at an 
age of 6-8 weeks, and immediately after arrival were allowed to adjust to conditions for at least 5 
days before they were used for experiments. Standardized diet (PROVIMI KLIBA) and 
autoclaved tap water were provided ad libitum. Mice were group-housed (8 mice per cage) under 
pathogen-free and controlled environmental conditions (21 ± 1.5°C temperature, 55 ± 10% 
humidity) and handled according to the institutional, governmental and European Union 
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guidelines (Austrian Animal Protection Laws, GV-SOLAS and FELASA guidelines). Animal 
studies were approved by the internal ethics committee and the local governmental committee. 
Two different vaccination schedules were tested. In the first scenario mice were vaccinated 
subcutaneous (s.c.) only once, with either buffer as control, with the Ova Protein (50µg), with 
the SIINFEKL Replicon (100µg), or with the VLP containing the SIINFEKL replicon (100µg). 
The volume of all applications was 100µL, and after one week the mice were euthanized and 
spleens were harvested for FACS analysis. In the second vaccination scenario mice were 
vaccinated with buffer as control or with buffer containing VLPs containing the SIINFEKL 
replicon RNA (100µg). The vaccinations were administered s.c. with a volume of 100µL for 3 
consecutive weeks (q7d), and one week after the last injection the mice were sacrificed and their 
spleens were harvested for FACS analysis. In addition one C57BL/6Tg(TcraTcrb)1100Mjb/Crl 
(OT-1) mouse provided by Charles River Laboratories (France) and one C57BL/6Tac mouse 
were euthanized and their spleens harvested to collect T-cells as control for the FACS analysis. 
 
In vitro stimulation and single-cell analysis by flow cytometry 
Splenocytes from vaccinated and control mice were obtained by tissue homogenization followed 
by red blood cell lysis (ammonium-chloride-potassium lysis). Ovalbumin specific CD8+ T cells, 
present in the cell suspensions, were stimulated with 8µg/ml of SIINFEKL(Ova 257-264, 
InvivoGen) and TEWTSSNVMEERKIKV(EMC microcollections) peptides together with 
10µg/ml anti-CD28 antibody (BioLegend) for 6 hours. One hour after start of stimulation, a 
protein-transport-inhibitor cocktail (eBioscience), containing Brefeldin A and Monensin, was 
added to block cytokine release. Before surface-marker staining, dead cells were labeled with a 
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fixable viability stain and Fc receptors were blocked (TruStain fcX, BioLegend) to avoid 
nonspecific binding. Key surface markers were stained with fluorescently labeled antibodies, 
followed by fixation/permeabilization (BD Cytofix/Cytoperm Plus, BD Biosciences) and 
intracellular cytokine staining (FITC anti-mouse IFNγ and PE-Cy7 anti-mouse TNFα, 
eBioscience). 
For immunophenotyping including the detection of H-2Kb/SIINFEKL specific CD8 T cells, 
spleens were dissociated using a spleen dissociation kit from Miltenyi biotec, together with a 
gentle MACS Dissociator. After red blood cell lysis, labeling of dead cells and Fc Receptor 
blockade, single cell suspensions were incubated with H-2Kb/SIINFEKL pentamer (ProImmune) 
for 30 minutes at 4 to 8oC. After thorough removal of unbound pentamer, key surface markers 
were labeled fluorescently with specific antibodies.Flow data were collected with a BD 
LSRFortessa cell analyzer and further analyzed using FlowJo 10 and GraphPad Prism 7.03. 
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3.7 Supporting Information 
 
 
Figure S1. Antibody Titers.  Four C57BL/6Tac mice were immunized subcutaneously with 
CCMV VLPs containing a non-translated RNA (20 µg/per mouse/per immunization) on weeks 0, 
2, and 4. Sera were tested for binding to CCMV VLPs 1 week after the 3rd immunization. Pre-
immune serum (“Naïve”) was used as a negative control.  
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Figure S2. TOP: Expression intensity of activation markers on DCs treated with CCMV 
VLPs carrying eYFP-Replicon mRNA. The median fluorescence intensity (MFI) of CD86 
(left), MHC II (middle) and CD80 (right) was determined for DCs treated with media only (black 
bars), CCMV VLPs carrying eYFP replicon mRNA (blue bars), and CCMV VLPs carrying 
eYFP replicon mRNA that have been pre-incubated with anti-CCMV VLP (red bars) antibodies 
or naïve antibodies (grey bars).  
BOTTOM: RNA quantitative PCR (qPCR). DCs treated as above were lysed and eYFP-
specific mRNA levels were determined by qPCR – note break in vertical scale. The p value was 
determined using a one-way Anova test.  
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Figure S3. Cytokine production of SIINFEKL responsive CD8+ T cells. T-cells were 
stimulated with SIINFEKL peptide for 6 hours. The amount of INF-gamma and TNF-alpha 
double-positive cells is shown as percentage of total CD8+ T cells. Samples analyzed in this 
assay have been obtained from the same animal experiment described in Figure 14, with “Ctr” 
and “SIINFEKL-VLP” denoting the multiple vaccinations involving buffer-solution and OVA-
replicon-VLP, respectively. 
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Figure S4. Low frequency of H-2Kb/SIINFEKL-specific CD8+ T cells in mice vaccinated 
only one time. The fraction of SIINFEKL specific T-cells in spleen samples, collected one week 
following  a one time only vaccination, was determined by flow cytometry. The graph shows 
scatter plots for single vaccinations with negative control (“Ctr”, 100 µL of buffer solution) 
positive control (50 µg of “OVA Protein”), 100 µg of SIINFEKL replicon RNA and 100 µg of 
SIINFEKL-VLPs. The difference of less than 0.1% between the SIINFEKL-VLP outcome and 
that for the negative control is to be contrasted with the 0.4% difference found for the multiple-
boost vaccination with the same VLPs (see Figure 14). To compare all groups an Anova test was 
performed together with a Dunnett’s test to correct for multiple comparisons (p= 0.0484) 
between the “Ctr” and the “SIINFEKL-VLP” groups.  
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Chapter 4: Two-molecule replicon for co-delivery of 
replicon and large genes 
4.1 Construction of dual replicated RNA molecules 
Since RNA1 of Nodamura virus (NoV) is already about the size (3000nt) of each 
genomic RNA packaged into CCMV, there is a limitation on the size of the GOI inserted.  Our 
lab has demonstrated that in vitro assemblies of RNA above 4500 nt in length result in a major 
population of capsid multimers, i.e., two or more T=3 capsids sharing a single RNA molecule 
These multimers are more susceptible to RNase degradation, so maintaining single T=3 capsids 
requires packaging RNA between about 2000-4500 nts in length, which limits the size of the 
GOI we can add and/or the number of added GOIs.  
A promising avenue to allow for amplification of larger GOIs involves leaving RNA1 of 
NoV unchanged, and inserting the GOI into the RNA2 of NoV which is also replicated. A 
previous study[Rosskopf 2012] has shown that by preserving the untranslated regions of RNA2, 
even while substituting the capsid protein open reading frame with GFP, there is still replication 
of RNA2. These authors transfected the plasmids encoding combinations of full-length RNA1 
and varying regions of RNA2 into yeast. From their experiments they identified a 24-nt stem 
loop near the 3’ end that is necessary for replication. While demonstrating replication with just 
the sequence of the untranslated 3’ end that includes the stem loop, they showed that preserving 
in addition some of the sequence for the capsid protein gene (for a total of 236 nts) resulted in 
more replication. 
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Figure 15: Schematic of a proposed two-molecule system for amplification of a gene 
inserted into RNA2 of NoV. LEFT is the RNA2-GOI, and RIGHT shows either a WT RNA1 
molecule or GOI-RdRp molecule that would help to replicate the complementary RNA2 
molecule. 
 
4.2 Reporter gene studies of two-molecule replicons 
The replicon-VLP strategy involves an RNA1, either wild-type or with a single-molecule 
replicon containing a desired gene, and a separate RNA2-GOI. This RNA2 construct – depicted 
in figure 15 - includes a GOI replacing the capsid protein gene of nodamura, and to promote 
replication this gene is flanked by the 5’ untranslated region (UTR) 17 nts  from the beginning 
and 236 nts (which includes the end of the capsid gene and the whole 3’ UTR) from the end of 
RNA2. Co-transfection of wild-type RNA1 with RNA2 modified to include luciferase revealed 
greater expression than either luciferase mRNA or the modified RNA2 alone (figure 16).  
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Figure 16: Time course of luciferase expression in BHK 21 cells. Luciferase mRNA, RNA2 
luciferase, or WT RNA1 + RNA2 luciferase were all separately transfected with lipofectamine in 
equal copy number.   
Although we have shown that the protein expression when the luciferase-RNA2 is 
coupled with wild-type (WT) RNA1, further experiments need to be performed to determine its 
potential for therapeutic applications. As in the experiments in which the single-molecule EYFP-
replicon was utilized to track the replication cycle of the replicon and health of transfected cells, 
a fluorescent protein can be inserted into RNA2 to observe a similar phenomenon for the two-
molecule replicon system. An EYFP-replicon can be co-transfected with an RNA2 encoding a 
different fluorescent protein (mCherry fluorescent protein), in order to concurrently visualize 
protein expression from both molecules. This method would not only allow verification of each 
molecule being expressed within a certain cell, but also might demonstrate colocalization of the 
complementary molecules. The above experiment with two fluorescent genes can be performed 
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in vitro by either transfecting each mRNA into BHK cells, or incubating each VLP with dendritic 
cells (possibly at separate times). 
This two-molecule strategy may hold promise for a vaccine system. Eventually, a two-
molecule ovalbumin system would probably involve separately packaged WT RNA1 and 
antigen-RNA2. Since we have demonstrated that an ovalbumin epitope-repeat in RNA1 can 
elicit a killer T cell response, this single-molecule replicon can be paired with an RNA2 
containing either an additional antigen and/or adjuvant to boost the immune response.  
 The considerations for keeping the length of gene inserted into RNA1 short enough to 
keep it packageable into a single T=3 capsid, or putting the gene into RNA2 apply as well to 
maintaining a preferred size of RNA2. Many genes encoding useful antigens or adjuvants are in 
the range of 1000-1500 nts, which results in an RNA2 molecule that is less than 2000 nts. For 
assemblies of RNA lengths around 2000 nts and below, the populations of capsids are 
heterogeneous and show a significant portion of capsids that are 6-10 nm smaller (presumed to 
be T=2 capsids) than wild-type T=3 virus. In order to maintain an optimal length for packaging 
the RNA2, one option is to make a dual protein construct. With two copies of genes of around 
1000-1500 nts, along with the untranslated replication elements, one achieves an ideal size 
(~3000nt) for assembly. One approach for including two genes involves making a fusion protein 
construct that has the same self-cleaving T2A peptide as in the single-molecule replicon, to 
separate the two protein products. Another option is to separate the two genes by an internal 
ribosome entry site (IRES). This is an RNA element that would allow for separate translation of 
the second gene in RNA2 in a cap-independent manner. While the fusion protein would have one  
read-through translation event to generate both proteins, the IRES-RNA2 would involve separate 
ribosomes binding and initiating translation events at the 5’ capped end  and at the IRES. 
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One candidate gene for the use of a two-molecule system as part of a viral vaccine is the 
HIV envelope protein glycoprotein 120 (gp120). HIV gp120 is a widely studied envelope protein 
involved in viral entry into immune cells via binding of the CD 4 receptor[Kwong 1998]. The 
length of the gp120 gene is ~1400 nt, which is too long to insert into RNA1 of NoV and still 
have it packaged into single T=3 capsids. When inserted into RNA2, the total length is below 
2000 nt. To make a molecule long enough for efficient packaging into a T=3 structure, we 
explored generating a fusion protein. This fusion protein could include a second copy of gp120, 
some other antigen, or even adjuvant. To test the efficacy of a fusion protein in an RNA2 
molecule, we cloned an RNA2 that included the gp120 gene separated from the eYFP gene by a 
T2A peptide. From the fluorescence exhibited after 20 hours, we demonstrated that the second 
gene can be translated (figure 17). In addition, an analogous transfection was performed using 
equal numbers of single-molecule eYFP-replicon and RNA2 ENV-eYFP. Corroborating the 
luciferase results of single-molecule (figure 4) and two-molecule transfections (figure 16), we 
see that the protein expression is less robust in the two-molecule scenario (figure 16). This 
appears to be another possible method for attenuation of the replicon in gene-delivery efforts 
where the health of the target cell is a concern.          
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A 
RNA2 Env-eYFP + replicon               Brightfield image 
          
B 
eYFP-replicon                           Brightfield image 
          
Figure 17: Fluorescence and brightfield microscope images of BHK 21 cells transfected 
with replicon after 20 hours. A shows the fluorescence exhibited by a lipofectamine 
transfection of WT RNA1 and an RNA2 molecule containing the fusion HIV envelope protein 
and eYFP genes separated by a T2A self-cleaving peptide. B shows a transfection done in 
parallel with an equal copy number of eYFP-replicon.  
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Chapter 5: Generation and characterization of 
cysteine mutant CCMV 
While having a protected mRNA cargo is important for gene delivery, there is still a 
question of the replicon-VLP making it into the proper cells. In the vaccine approach of delivery 
to dendritic cells as a means of eliciting a specific killer T cell response, the necessity for specific 
targeting is lessened because the dendritic cells are primed to endocytose virus-like capsids.  In 
other gene delivery scenarios, targeting specific cell types or cancerous cells may be desired. 
One approach for targeting a VLP to cells is conjugation of antibodies (complete or partial) to 
the capsid surface. In order to perform a conjugation to CCMV, there is a benefit to modifying 
the CP. 
 
5.1 Site-directed mutagenesis of CCMV cDNA plasmid 
The most commonly used amino acid residues for conjugation to antibodies are lysine 
and cysteine. One method of labeling proteins utilizes the primary amines that exist in the side 
chains of lysines. CCMV has several surface-exposed lysines present in each capsid protein 
subunit, and the Gelbart/Knobler group has used NHS esters (N-hydroxysuccinimide esters) 
conjugated to fluorophores for labeling of capsids. An effect observed from this NHS ester-
mediated fluorophore labeling is a decreased ability of capsid disassembly with greater amounts 
of labeling. CCMV does not have any surface-exposed cysteines, so there has been interest in 
introducing a cysteine for potential functionalization/labeling of capsids. A Michael-addition of 
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thiol to a maleimide is commonly used for bioconjugation, and two FDA-approved antibody-
drug conjugates – Brentuximab vedotin and Trastuzumab emtansine – contain a thiol-maleimide 
adduct (Fontaine 2015). A group at Montana State University introduced cysteines onto each 
CCMV CP subunit to form a 2D-array on a gold surface utilizing the exposed thiols (Douglas 
2003). A single labeling site on each CP subunit can be obtained by site-directed mutagenesis, 
thus controlling the amount of eventual conjugation. Furthermore, one can do a mixed assembly 
of cysteine-CP with wild-type CP to further limit the number of accessible sites for thiol-
maleimide labeling.               
To this aim we set out to introduce a cysteine into each CCMV CP by a method similar to 
the one employed by Douglas, et al. They used site-directed mutagenesis to change residue 163 
from alanine to cysteine. Our group has plasmids which contain cDNA clones of RNA1, RNA2, 
and RNA3 generated by the Ahlquist group (reference needed). For the site-directed 
mutagenesis, primers were designed that anneal to both strands at residue 163 of RNA3’s cDNA 
plasmid (named PCC3). The whole plasmid is amplified by PCR, now incorporating the amino 
acid change to cysteine present in the primer sequences. The PCR mixture is then digested by 
DpnI, which digests the parental DNA due to methylation during its E. Coli expression. After 
digestion, the mutated molecules are transformed into competent E. Coli cells, which will repair 
the nick formed during PCR. As with any cloning, colonies are grown up and the sequence is 
verified to ensure successful mutagenesis of A163C.  
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5.2 Transfection and purification of CCMV from cowpea plants 
The plasmids containing cDNA of RNA1, RNA2, and RNA3 with a A163C mutation, 
were linearized at the XbaI site. Then they each underwent capped transcription, and were 
purified. In a protocol similar to that used for infection of cowpea plants, leaves were punctured 
by a microchip and a solution containing an equal amount of each mRNA was pipetted onto 
them and scraped with the pipette tip. After a week, classic mottling indicating infection was 
observed. After two weeks, the leaves were harvested, but the amount of virus in these few 
leaves was not enough for a purification. So the leaves were crushed in expectation that cysteine-
modified CCMV could be released into a solution that could be used to infect more cowpea 
plants by the same means. These latter plants also displayed mottling, and two weeks after 
infection the leaves were harvested. 
The procedure for purifying the cysteine-mutant virus was essentially the same as for 
wild-type CCMV. This involves taking infected leaves stored at -80 ˚C and crushing them with a 
mortar and pestle in a low pH, high molarity sodium and magnesium acetate buffer called virus 
extraction buffer. The crushed leaf mixture was then stirred with an equal volume of chloroform, 
then centrifuged to isolate the virus-containing aqueous solution. The virus was pelleted by 
ultracentrifugation, with aid of a sucrose cushion layer. These pellets were resolubilized in a 10-
times-more-dilute buffer than virus extraction buffer, called virus suspension buffer. This 
solution was pipetted on top of a 10-40 percent sucrose gradient, formed by a freezing-then-
thawing of 25 percent sucrose-VSB. Rayleigh scattering allows the band in the gradient 
containing the virus to be seen, allowing it to be pipetted. At this point we observed something 
different from purifications of wild-type virus. Instead of a single blue virus band, multiple bands 
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were observed, which we speculated are associated with different clusters of CCMV formed 
from disulfide bridges due to the cysteines on the capsid surface. When samples of the cysteine-
mutant CCMV were run on an agarose gel next to wild-type, the band for A163C CCMV ran a 
bit faster than wild-type. This may be due to the isoelectric point being slightly changed when 
the nonpolar alanine is substituted for the polar cysteine amino acid. No additional bands were 
visualized in the gel for A163C CCMV, unlike in the sucrose gradient.    
Although we established the above differences in the cysteine mutant, we wanted visual 
confirmation of the formation of capsids and the incorporation of 180 cysteine groups. It is well-
known that thiols form a nearly irreversible bond to gold, so evidence of gold-labeling would 
confirm that unique cysteines have been added to the capsid surface. With the help of Dr. 
Christian Beren, conjugation of gold nanoparticles to the cysteines was undertaken. The protocol 
involved incubating citrate-stabilized 5-nm gold nanoparticles with an excess of cysteine-CCMV 
in a neutral pH phosphate buffer. This mixture is centrifuged at 13000 rpm, which is fast enough 
for only the gold nanoparticles to pellet. This pellet is resolubilized and imaged by negative-stain 
electron microscopy (EM). Gold particles were observed associated with the properly sized and 
ordered virus capsids – as seen in figure 18. While there are 180 potential sites of gold-thiol 
binding on cysteine-mutant CCMV, we only observed a few gold particles bound to each capsid. 
Since our aim for this experiment was only to confirm the introduction of surface-exposed 
cysteines to CCMV, the clustering of gold particle onto the virions was sufficient to confirm the 
presence of cysteines.  
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Figure 18: Electron micrograph of Cysteine-mutant CCMV labeled with 5-nm citrate-
coated gold nanoparticles.  
 
5.3 Self-assembly of cysteine-mutant CCMV alone and with WT capsid 
protein 
Experiments were done to see if the cysteine-mutant CCMV CP (which we will refer to 
as CP*) can be used to self-assemble around RNA. Dissassembly of the cysteinylated mutant 
virions by dialysis into a high calcium buffer, followed by ultracentrifugation, successfully 
separated the CP* from viral RNA. Assembly was carried out using the same mass ratio – 4.3:1 
CP:RNA –  known for wild-type CP to fully encapsidate RNA. Lane 3 in the gel in Figure 19 
shows that the CP* is able to fully encapsidate BMV RNA1 (B1 RNA). The CP* assemblies 
contribute a band that runs faster than WT assemblies (lane 6), as was the case for cysteine-
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CCMV and wild-type CCMV. Again, this may be due to the isoelectric point being slightly 
changed by substitution of alanine to cysteine. In lane 3, we observe incomplete packaging of the 
B1 RNA, because the 2.8:1 CP*:RNA mass ratio is sub-stoichiometric for complete assembly. 
The appearance of the relatively smeared band of lane 2, located intermediate between the fully 
assembled (lane 3) and naked RNA (lane 5), is similar to that observed with WT CP assembly 
mixtures that include a sub-stoichiometric amount of CP[Garmann 2014].   
One consideration when generating cysteine-CCMV is that purification yield about 3-4 
times fewer CP less than wild-type from an equal mass of infected leaves. For this reason, and as 
another means to control the amount of labeling of CCMV, we attempted assembly using a 
mixture of CP and CP*. The single band in lane 7 resulting after an assembly with a 50-50 
mixture of CP and CP* indicates well-formed particles. Also, the position of the band 
intermediate between those for the assemblies using either WT CP (lane 6) or CP* (lane 3) 
demonstrates that both forms of CP are incorporated into each VLP. If WT CP and CP* 
separately packaged individual RNA, we would see a band running in line with the slower WT 
CP assembly (lane 6), and a band in line with the faster migrating CP* assembly (lane 3).  
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Figure 19: A 1% agarose gel comparing WT CP and cysteine-mutant CP assemblies. 
Description of the contents of each line described in text. 
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Chapter 6: Future Directions and Conclusions 
6.1 Future Directions: alterations to the replicon and two-molecule 
fluorescence co-expression studies 
When utilizing the replicon as part of a gene therapy, it may be important to be able to 
calibrate the activity. As discussed in Chapter 3, dilution of the replicon has an effect on the 
duration of amplification. Also, the quantity of reporter gene expression from increasing 
dilutions changes in a non-linear manner. In addition to changing dosages, direct modifications 
to the GOI replicons can be made for various desired effects. One change to the replicon is re-
incorporation of the NoV B2 RNAi-silencing protein by changing the translation promoter 
region back into the wild-type sequence. It has been demonstrated that in some mammalian cell 
lines greater replication of NoV can be achieved with the B2 protein than without it[Johnson 
2004]. As detailed in Chapter 3. the start of the replicon construct can also be modified by 
incorporating two extra guanidine (G) nucleotides to the end of the T7 promoter. These extra 
nucleotides have been shown to increase the yield from in vitro transcription about three-fold, 
but these extra Gs are also incorporated into the beginning of the replicon transcript. We found 
that replication activity was reduced by about 40% with this alteration, so this can be a means of 
reducing the activity of the replicon with the added benefit of greater yields from capped 
transcription.  
 While the above-described in vitro experiments suggest that a two-molecule VLP system 
could be applied to in vivo applications such as intravenous administration of a therapeutic, there 
are still concerns that need to be addressed. One concern is that a cell might only receive one 
 
 
67 
 
type of the two molecules (either the replicon or the GOI-RNA2). By fluorescence-activated cell 
sorting (FACS), one can compare the number of cells expressing one or both of the two 
fluorescent proteins. It would also be interesting to see colocalization of the two molecules’ 
fluorescence, suggesting that replication of the RNA2 molecule is occurring. Although this 
would not be an absolute determination, if most of the fluorescence is co-localized then this  
would suggest that the cell and/or VLP might have a way of bringing together the particles. A 
study showed that NoV’s RdRp forms functional replication complexes at the outer 
mitochondrial membrane of cells[Gant 2014]. It is likely that viral RNA or VLPs would want to 
localize there to coopt host ribosomes and allow for replication by the RdRp.    
 
6.2 Conclusions 
All of the work presented throughout these chapters plays some role in the understanding 
and potential utilization of a combined Nodamura virus replicon and CCMV VLP gene delivery 
system.  From the quantitative and qualitative studies of the replicon in BHK 21 cells in Chapter 
2, we confirm that the replicon does significantly increase expression of reporter proteins over an 
equal number of mRNA containing only the reporter gene.  From these studies we also observed 
a non-linear dose dependence of the replicon. At significant dilutions of replicon molecules (40 
fold) compared to a typical transfection, the relative light units measured reveals an extended 
lifetime of replication, and even reaches about half the total luciferase yield.  
When packaging the replicon into a CCMV VLP, we observe some interesting trends for 
its potential as part of a vaccine (Chapter 3). A tandem repeat of ovalbumin’s SIINFEKL epitope 
was inserted into the subgenomic region of RNA1, and this replicon packaged into VLPs was 
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able to passively be taken up by human dendritic cells during a 24-hour incubation. The replicon-
VLPs caused increases in the maturation markers CD 80, CD 86, and MHC II, as well as 
revealed by qPCR many copies of SIINFEKL-containing RNA. When the VLPs were pre-
incubated with anti-CCMV antibodies, the increase of maturation markers and RNA amounts 
were further increased compared to replicon-VLPs alone. These results demonstrate that CCMV 
VLPs can be taken up by dendritic cells, where replication then occurs to promote increased 
production of antigen. Also, if one were to administer repeated dosages of this vaccine, some 
antibodies decorating the VLPs do not prevent its uptake, or subsequent replication of its RNA 
cargo.   
Length is a consideration when packaging RNA with CCMV CP. If the RNA is overly 
short or long, the VLP will no longer be the wild type, well-formed individual T=3 capsids. 
Since many genes are too long to be inserted into the RNA1 of NoV and still be packaged into 
T=3 single capsids, an alternative is to utilize the RNA2 of NoV. Using 5’ and 3’ elements of 
RNA2 known to promote replication by its associated RdRp, we demonstrated that a luciferase 
gene inserted into this RNA2 molecule (when transfected along with RNA1), yielded greater 
luciferase activity than the luciferase gene alone.  
For some therapeutic applications, specific targeting of the VLP to certain cells may be 
important. In preparation for this aim, a cysteine-mutant version of CCMV was made. Site-
directed mutagenesis of the cDNA clone of the capsid protein-encoding RNA3 was used to allow 
for a substation of alanine 163 to cysteine. Gold-labeling of the resulting cysteine-mutant CCMV 
showed that unique surface-exposed cysteines were introduced to form gold-thiol bonds. This 
cysteine-mutant CP could be disassembled, and undergo assembly in a similar manner to WT 
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CP. In fact, the two CPs (WT and cysteine-CP) can be assembled in mixtures to control the 
amounts of labeling sites for subsequent conjugations of targeting ligands to cysteine.      
  While this work represents a promising platform for gene therapy applications, further 
work still needs to be done. The in vivo T-cell response to the SIINFEKL-Replicon-VLP was 
statistically significant, but still modest. Further experiments to boost this immune response may 
involve conjugation of ligands to target the VLPs to dendritic cells, or introduction of an 
adjuvant gene to help stimulate dendritic cells that have also received the desired antigen.  
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